Drug details
Imbruvica (ibrutinib capsules)
type of Antineoplastic Tyrosine Kinase Inhibitors
Imbruvica (ibrutinib) is an inhibitor of Bruton's tyrosine kinase (BTK) used to treat patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This drug may have the following side effects:
- shortness of breath,
- nausea,
- vomiting,
- indigestion,
- diarrhea,
- weakness,
- cough,
- constipation,
- joint pain,
- anemia,
- fever,
- nosebleed,
- rash,
- headache.
- fatigue,
- abdominal pain,
- dizziness, and
- urinary tract infection,
- sinus infection,
- upper respiratory tract infection,
- bruising,
- muscle spasms,
- decreased appetite,
- musculoskeletal pain,
- pneumonia,
- low platelet count,
- neutropenia,
- swelling of the extremities,
- swelling of the mouth and lips,
- skin infections,
- dehydration,
The following drugs are related to Imbruvica, either as a replacement or used together:
- Aliqopa (copanlisib for injection, for intravenous use)
- Belrapzo (bendamustine hydrochloride injection)
- Rezurock (belumosudil tablets)
- Treanda (bendamustine hydrochloride injection)
- Vivimusta (bendamustine hydrochloride injection)
- Velcade (bortezomib)
- Tecartus (brexucabtagene autoleucel suspension)
- Brukinsa (zanubrutinib capsules)
- Cytoxan (cyclophosphamide)
- Revlimid (lenalidomide)
- Zynlonta (loncastuximab tesirine-lpyl for injection)
- Rituxan (rituximab)
- Truxima (rituximab-abbs injection)
- Ukoniq (umbralisib tablets)
- Venclexta (venetoclax tablets)